Overview

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers

Status:
Completed

Trial end date:
2008-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer

Treatments:

Glucagon
Glucagon-Like Peptide 1